I am not discounting a "mix" of administration. I only made a "brief" guesstimate in reference to the funded cost of trial.
I personally doubt that a diverse CRO other than population centers will be found acceptable. Anavex certainly needs a competent contractor for all the high hopes many place. If they think the delays in navigating the FDA are bad........